US Food and Drug Administration (FDA)Suspended authorizations for previously authorized antibody treatments on the grounds that they were ineffective against the Omicron variant. According to the information shared today, the monoclonal antibody bebtelovimab Emergency use has been granted.
Bebtelovimab was developed by the team in collaboration with biotech company AbCellera and Eli Lilly, who found the first commercially available antibody for the coronavirus.
Covid-19 detection is now possible with breath measurement!
Breath-taking COVID-19 tracking devices that provide results in just 5 minutes may soon become widespread all over the world. Here is the new Covid-19 diagnostic method.
The bebtelovimab antibody for the Omicron variant has proven itself
Commenting on the subject Carl Hansen, CEO of Abellera, “We started work on the development of the new monoclonal therapy in the first months of 2021. To avoid future variants, we only think that they mutate infrequently. SARS-CoV-2 spike We will develop an antibody that binds to specific sites in the protein. We’re making an effort to discover a next-generation antibody.” used the phrases.
Hansen underlined that the developed antibody is effective in all known worrying variants. Bebtelovimab, the only antibody also effective for the Omicron variant, has achieved immediate use authorization with some limitations.
The developed antibody therapy will be applied to people who experience mild to moderate symptoms in the early stages of the coronavirus. For antibody therapy 12 years and older includes the limitation.
Authorities have announced that bebtelovimab will not be used in people who have already been hospitalized for coronavirus. It can be used for patients who are inaccessible to other coronavirus treatment options approved or authorized by the FDA.
The Omicron variant has multiple iterations. the first iteration to BA.1 Unfortunately, it is not effective against the other Omicron variant BA.2. Scientists, Sotrovimab He stated that if the treatment does not meet the expectations, the methods used by the health sector against the coronavirus will be limited.
US Department of Health and Human Services, “If the BA.2 subvariant continues to increase in the US, we will use this potential therapy as a monoclonal antibody therapy that works against this strain of the virus.” said.